Ir(piq)2(pytr-Sq-girentuximab)

Ir(piq)2(pytr-Sq-girentuximab) is a phosphorescent organometallic iridium(III) antibody-drug conjugate (ADC) designed for the dual purposes of photodynamic detection (PDD) and photodynamic therapy (PDT) of tumors that overexpress carbonic anhydrase IX (CAIX). The agent consists of the monoclonal antibody girentuximab, which targets the CAIX enzyme, conjugated to a phosphorescent iridium(III) complex featuring 1-phenylisoquinoline (piq) cyclometalating ligands and a 2-pyridyl-1,2,3-triazole (pytr) ancillary ligand. The conjugation is achieved via a squaramide ethyl ester (Sq) linker that reacts with lysine residues on the antibody to form stable vinylogous amide linkages. As a theranostic agent, the iridium(III) component enables emissive detection to guide surgical resection and acts as a photosensitizer that, upon irradiation with visible light, generates reactive oxygen species to induce targeted tumor cell death. Primary research focuses on its application in clear cell renal cell carcinoma (ccRCC), glioblastoma, and triple-negative breast cancer.

Other names

iridium(III) girentuximab conjugateIr(III)-girentuximab conjugatephosphorescent iridium(III) antibody conjugate